The Skin’s Secret Weapon: Researchers Uncover an Ancient … – SciTechDaily

A variety of cells (white) proliferate at the ragged edge of a five-day-old wound, including epidermal stem cells (basal layer of epithelium in green), which secrete IL24. Credit: Laboratory of Elaine Fuchs

The world can be a hazardous place, with various dangers lurking around us such as bacteria, viruses, accidents, and injuries. Our skin acts as the ultimate shield, providing a steadfast defense against these threats. It serves as the boundary between the internal and external environment and is the largest organ in the body, functioning nearly seamlessly to protect us.

Still, the skin is not immune to harm. It endures daily assaults and still tries to keep us safe by detecting and responding to these dangers. One method is the detection of pathogens, which activates the immune system. However, recent research conducted by Elaine Fuchs at Rockefeller University and published in the journal Cell, has uncovered a new protection mechanism that responds to injury signals in damaged tissue, such as low oxygen levels caused by blood vessel disruption and scab formation. This mechanism is activated without the need for an infection.

The study is the first to identify a damage response pathway that is distinct from but parallel to the classical pathway triggered by pathogens.

At the helm of the response is interleukin-24 (IL24), whose gene is induced in skin epithelial stem cells at the wound edge. Once unleashed, this secreted protein begins to marshal a variety of different cells to begin the complex process of healing.

IL24 is predominately made by the wound-edge epidermal stem cells, but many cells of the skinthe epithelial cells, the fibroblasts, and the endothelial cellsexpress the IL24 receptor and respond to the signal. IL24 becomes an orchestrator that coordinates tissue repair, says Fuchs, head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development.

Scientists have long understood how the host responses protect our body from pathogen-induced threats: somatic cells recognize invading bacteria or viruses as foreign entities and induce a number of defense mechanisms with the help of signaling proteins such as type 1 interferons.

But how does the body respond to an injury that may or may not involve foreign invaders? If we cut a finger while slicing a cucumber, for example, we know it instantlytheres blood and pain. And yet how the detection of injury leads to healing is poorly understood on a molecular basis.

While type 1 interferons rely on the signaling factors STAT1 and STAT2 to regulate the defense against pathogens, previous research by the Fuchs lab had shown that a similar transcription factor known as STAT3 makes its appearance during wound repair. Siqi Liu, a co-first author in both studies, wanted to trace STAT3s pathway back to its origin.

IL24 stood out as a major upstream cytokine that induces STAT3 activation in the wounds.

In collaboration with Daniel Mucidas lab at Rockefeller, the researchers worked with mice under germ-free conditions and found that the wound-induced IL24 signaling cascade is independent of germs.

But what injury signals induced the cascade? Wounds often extend into the skin dermis, where capillaries and blood vessels are located.

We learned that the epidermal stem cells sense the hypoxic environment of the wound, says Yun Ha Hur, a research fellow in the lab and a co-first author on the paper.

When the blood vessels are severed and a scab forms, epidermal stem cells at the edge of the wound are starved of oxygen. This state of hypoxia is an alarm bell for cell health and induced a positive feedback loop involving transcription factors HIF1a and STAT3 to amplify IL24 production at the wound edge. The result was a coordinated effort by a variety of cell types expressing the IL24 receptor to repair the wound by replacing damaged epithelial cells, healing broken capillaries, and generating fibroblasts for new skin cells.

Collaborating with Craig Thompsons group at Memorial Sloan Kettering Cancer Center, the researchers showed that they could regulate Il24 gene expression by changing oxygen levels.

Once the researchers pinpointed the origin of the tissue-repair pathway in epidermal stem cells, they studied the wound repair process in mice that had been genetically modified to lack IL24 functionality. Without this key protein, the healing process was sluggish and delayed, taking days longer than in normal mice to completely restore the skin.

They speculate that IL24 might be involved in the injury response in other body organs featuring epithelial layers, which act as a protective sheath. In recent studies, elevated IL24 activity has been spotted in epithelial lung tissue of patients with severe COVID-19 and in colonic tissue in patients with ulcerative colitis, a chronic inflammatory bowel disease.

IL24 could be working as a cue to signal the need for injury repair in many organs, Hur says.

Our findings provide insights into an important tissue damage sensing and repair signaling pathway that is independent of infections, explains Fuchs.

An analysis with evolutionary biologist Qian Cong at UT Southwestern Medical Center revealed that IL24 and its receptors share close sequence and structure homology with the interferon family. Though they may not always be working in coordination at every moment, IL24 and interferons are evolutionarily related and bind to receptors sitting near each other on the surface of cells. The researchers suspect that these signaling molecules derive from a common molecular pathway dating far back in our past.

We think that hundreds of millions of years ago, this ancestor might have diverged into two pathwaysone being pathogen defense and the other being tissue injury, Liu says.

Perhaps the split occurred to cope with an explosion of pathogens and injuries that caused a sea of troubles for life on Earth.

Reference: A tissue injury sensing and repair pathway distinct from host pathogen defense by Siqi Liu, Yun Ha Hur, Xin Cai, Qian Cong, Yihao Yang, Chiwei Xu, Angelina M. Bilate, Kevin Andrew Uy Gonzales, S. Martina Parigi, Christopher J. Cowley, Brian Hurwitz, Ji-Dung Luo, Tiffany Tseng, Shiri Gur-Cohen, Megan Sribour, Tatiana Omelchenko, John Levorse, Hilda Amalia Pasolli, Craig B. Thompson, Daniel Mucida and Elaine Fuchs, 24 April 2023, Cell.DOI: 10.1016/j.cell.2023.03.031

Originally posted here:
The Skin's Secret Weapon: Researchers Uncover an Ancient ... - SciTechDaily

Global Breast Cancer Market Size Projected To Hit $70 Billion in … – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Palm Beach, FL - May 5, 2023 FinancialNewsMedia.com News Commentary Breast cancer is the most commonly occurring disorder among the population majorly seen in females with rising disorder. It is a disorder that spreads the disease with increasing symptoms such as pain in the bones swelling of lymph nodes, breathing problems, and many more. Breast cancer development takes place with the presence of genes like Human Epidermal growth factor receptor 2 (HER2). Stimulation of cancer in the body with the presence of this protein extends the proliferation of the cells. Positive HER2 receptor patients having the most aggression in breast cancer than other types of breast cancer. Numerous treatments are available which are used to treat and eradicate the tumor and increase the target on HER2. Which enlarges the market of Breast cancer with an increasing number of patients every year with an increase in the recovery rate of breast cancer. A report from Precedence Research projects that the global breast cancer market size was estimated at USD 31.89 billion in 2022 and is projected to hit around USD 70.51 billion by 2030 with a registered CAGR of 10.43% during the forecast period 2022 to 2030. The report said: "Enhance research and development with increased new technologies and therapies developed in breast cancer which is prominently contributing to enhancing the market growth with increased demands from the medical sector for treating the patients with new treatments and medications. Government support with increasing providence for new developments in medications and increased efficiency and efficacy of the treatment and integration of newly developed medications in the medical sector." Active biotech and pharma companies in the markets this week include Oncolytics Biotech(R) Inc. (NASDAQ: ONCY) (TSX: ONC), Bristol Myers Squibb (NYSE: BMY), NANO-X IMAGING LTD (NASDAQ: NNOX), Soligenix, Inc. (NASDAQ: SNGX), Cardiff Oncology, Inc. (NASDAQ: CRDF).

Precedence Research said that key insights were: "By therapy, the targeted therapy segments involved the largest market; By cancer type, the hormone receptor segments extend the market share at the largest rate; By distribution channel, the hospital pharmacies segments developed their own pharmacies in the hospital with the highest market share; and By geography, The North American region holds the highest position in the market with increased market share. On the basis of geography, North America holds the highest position in the market with an increased market share in breast cancer. Advanced developed technologies in the market with an increased number of treatments available for treating breast cancer with an increasing number of patients helps to propel the market growth with increased government initiative in developing new drug developments and increased efficacy of the medications with increased results help to enhance the market growth."

Oncolytics Biotech(R) Inc. (NASDAQ: ONCY) (TSX: ONC) BREAKING NEWS: Oncolytics Biotech(R) Reports First Quarter 2023 Financial Results and Operational Highlights -

Oncolytics Biotech(R) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

"Our core programs in breast and pancreatic cancer are moving towards registrational studies with compelling clinical data and important milestones expected this year," said Dr. Matt Coffey, President and Chief Executive Officer. "The first of these milestones will come later this month when we report data from BRACELET-1, a randomized phase 2 trial expected to inform the design of a subsequent pivotal registrational study in HR+/HER2- metastatic breast cancer. Stakeholders across the breast cancer community have demonstrated a keen interest in this readout, which will add to a dataset that already includes statistically significant phase 2 results showing pelareorep's ability to drive a robust overall survival benefit in this indication. Notably, the BRACELET-1 abstract was selected for an oral presentation at the upcoming ASCO meeting, providing a highly prestigious venue to discuss the results with potential partners and the clinical community."

Dr. Coffey continued, "Looking into the second half of 2023, we expect to report updated results from GOBLET's first-line pancreatic cancer cohort and provide guidance on the optimal registration paths for our breast and pancreatic cancer programs. With these programs both targeting large markets with significant clinical unmet needs and supported by robust clinical proof-of-concept data, we believe confirming their paths towards approval will represent important value-creating events and substantially de-risk and maintain pelareorep's development pathway." CONTINUED... Read this full press release and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/

Other recent developments in the biotech industry of note include:

NANO-X IMAGING LTD (NASDAQ: NNOX) recently announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the multi-source Nanox.ARC, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system intended to produce tomographic images of the human musculoskeletal system adjunctive to conventional radiography on adult patients. Representing a major advancement in X-ray technology, Nanox.ARC is a multi-source digital 3D tomosynthesis system that utilizes novel, cold cathode X-ray tubes, which the Company intends to offer using an innovative pay-per-scan business model.

The FDA cleared Nanox.ARC for use in professional healthcare ??facilities or ??radiological ??environments, such as ??hospitals, clinics, imaging ??centers, and ??other medical practices?? by trained radiographers, ??radiologists, and physicians, and has the potential to increase availability to medical imaging around the world, once approved by local regulatory authorities and deployed at scale.

Soligenix, Inc. (NASDAQ: SNGX) recently announced positive clinical results from a compatibility study evaluating HyBryte (synthetic hypericin sodium) in the treatment of cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device, which recently received 510(k) clearance from U.S. Food and Drug Administration (FDA). The open-label study (protocol HPN-CTCL-02) enrolled 9 patients to receive 8 weeks of HyBryte treatment of their cancerous lesions, with an assessment of treatment response conducted at week 10 using the Composite Assessment of Index Lesion Severity (CAILS) score. All subjects were enrolled by Brian Poligone, MD, PhD, at the Rochester Skin Lymphoma Medical Group.

We were excited for the opportunity to work with Soligenix and make HyBryte available to our patients, stated Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group, Fairport, NY, and Principal Investigator for the compatibility study and Leading Enrolling Investigator in the FLASH study. Since the completion of the Phase 3 FLASH study, I have had a number of patients asking about possible access to this promising therapy. Fortunately, we were chosen to conduct this study and the patients enthusiasm for the product was evident by their willingness to participate in the trial, allowing for its rapid completion. I look forward to continuing to work with Soligenix to further advance the HyBryte program so my patients can have this much needed treatment option available to them.

Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, recently announced that the first patient was dosed this month with its investigational drug onvansertib in its Phase 2 ONSEMBLE trial (NCT05593328). The trial is designed to demonstrate a clinically meaningful difference in response and onvansertibs contribution to standard of care (SoC) FOLFIRI/bevacizumab for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC).

We are excited to be underway with our ONSEMBLE trial that builds on the promising efficacy and tolerability results demonstrated in our phase 1b/2 trial in mCRC, said Fairooz Kabbinavar, MD, Chief Medical Officer of Cardiff Oncology. mCRC is a difficult-to-treat cancer and patients in the second line setting need novel therapeutic options to improve clinical outcomes. Based on our open-label phase 1b/2 trial, we believe the combination of onvansertib with FOLFIRI/bevacizumab could positively impact patients responses to treatment and the durability of the responses. Nearly half of our planned 40 sites in the US are open to enroll patients and weve seen great enthusiasm from participating investigators.

Bristol Myers Squibb (NYSE: BMY) recently announced that the European Commission (EC) has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. This approval covers all European Union (EU) member states.

The approval is based on results from the pivotal Phase 3 TRANSFORM trial in which Breyanzi demonstrated statistically significant and clinically meaningful improvements in the study's primary endpoint of event-free survival (EFS), and key secondary endpoints of complete responses (CR) and progression-free survival (PFS) compared to standard therapy (consisting of salvage immunochemotherapy followed by high-dose chemotherapy and hematopoietic stem cell transplant [HSCT]), along with a manageable and well-established safety profile.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMs market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech(R) Inc. by a non-affiliated third party.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as may, future, plan or planned, will or should, expected, anticipates, draft, eventually or projected. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companys annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [emailprotected] +1(561)325-8757

SOURCE Financialnewsmedia.com

The post Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030 appeared first on Financial News Media.

COMTEX_431764985/2692/2023-05-05T08:46:29

Read the original post:
Global Breast Cancer Market Size Projected To Hit $70 Billion in ... - StreetInsider.com

Childrens Hospital Los Angeles Researchers Uncover New Clues to Origins of the Most Common Pediatric Kidney Cancer – Newswise

Newswise While Wilms tumoralso known as nephroblastoma-- is rare, it is the most prevalent childhood kidney cancer. Researchers at Childrens Hospital Los Angeles have now pinpointed a disruption in early kidney progenitor cell development that can be linked to the formation of Wilms tumor.

In a study published in Advanced Science, researchers at the GOFARR Laboratory in Urology compared kidney progenitor cells from a tumor with precursor cells from a healthy kidney. Normally, these precursor cells mature into kidney cells, but when their early development is dysregulated, they behave like cancer stem cells.

While most children with Wilms tumor are successfully treated, current therapies are aggressive. A minority of these patients have unfavorable prognoses or relapses; for these children, there is no existing therapy. By achieving a more precise understanding of how Wilms tumors develop, our goal is to find new treatments for all types of Wilms tumor, says Laura Perin, PhD, Co-Director of the GOFARR laboratory and senior study co-author with Stefano Da Sacco, PhD, another researcher at the GOFARR Laboratory.

Pediatric Wilms tumor can be considered a developmental cancer, says Dr. Perin, who is also Associate Professor at the Keck School of Medicine of USC. The normal adult kidney lacks kidney precursor cells, as they are exhausted before birth. But in Wilms tumors, instead of giving rise to a functional kidney, these precursor cells persist and form the tumor mass.

The researchers characterized these Wilms tumor kidney precursor cells, finding that these cells can reproduce the original tumor. They are aggressive, theyre drug-resistant, they metastasize like cancer cells, and they are able to create the full tumor that we see in patients, says Astgik Petrosyan, PhD, researcher at the GOFARR Lab and first author of the study.

The kidney precursor cells that generate Wilms tumors also abnormally expressed ITG1 and ITG4, proteins that help cells communicate with their microenvironment. This abnormal attachment to their microenvironment favors the uncontrolled replication of these cells and guides the formation of the tumor mass, says Dr. Da Sacco.

"Our findings provide a more accurate understanding of the different stages of both normal and abnormal kidney development, says Dr. Perin. This can possibly help the diagnosis of Wilms tumor, leading to more effective treatments for these patients.

Other study co-authors include: Valentina Villania, PhD, of CHLA; Paola Aguiari, PhD, of CHLA and David Geffen School of Medicine at UCLA - VA Healthcare System; Matthew E. Thornton, MS, of the Keck School of Medicine of USC; Yizhou

Wang, PhD, and Alex Rajewski, PhD, of Cedars-Sinai Medical Center; Shengmei Zhou, MD, of CHLA, Paolo Cravedi, MD, PhD of the Icahn School of Medicine at Mount Sinai; Brendan H. Grubbs, MD, of the Keck School of Medicine of USC; Roger E. De Filippo, MD, Sargis Sedrakyan, PhD and Kevin V. Lemley, MD, PhD, of CHLA and the Keck School of Medicine at USC; and Marie Csete, MD, PhD of USC.

About Childrens Hospital Los Angeles

Childrens Hospital Los Angeles is at the forefront of pediatric medicine, offering acclaimed care to children from across the world, the country and the greater Southern California region. Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County, the No. 1 pediatric hospital in the Pacific region and California, and among the top 10 in the nation on U.S. News & World Reports Honor Roll of Best Childrens Hospitals. Clinical expertise spans the pediatric care continuum for newborns to young adults, from everyday preventive medicine to the most advanced cases. Inclusive, kid- and family-friendly clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC, and proven discoveries reach patients faster through The Saban Research Institute of Childrens Hospital Los Angelesamong the top 10 childrens hospitals for National Institutes of Health funding. The hospital also is home to the largest pediatric residency training program at a freestanding childrens hospital in the western United States. To learn more, follow us onFacebook,Instagram,LinkedIn,YouTubeandTwitter, and visit our blog atCHLA.org/blog.

Read this article:
Childrens Hospital Los Angeles Researchers Uncover New Clues to Origins of the Most Common Pediatric Kidney Cancer - Newswise

Uncovering the transcriptional regulatory network involved in … – Nature.com

Haberlandt, G. in Plant Tissue Culture: 100 Years Since Gottlieb Haberlandt (eds Laimer, M. & Rcker, W.) 124 (Springer, 2003); https://doi.org/10.1007/978-3-7091-6040-4_1

Bidabadi, S. S. & Jain, S. M. Cellular, molecular, and physiological aspects of in vitro plant regeneration. Plants 9, 702 (2020).

Article CAS PubMed PubMed Central Google Scholar

Thorpe, T. A. History of plant tissue culture. Mol. Biotechnol. 37, 169180 (2007).

Article CAS PubMed Google Scholar

Radhakrishnan, D. et al. Shoot regeneration: a journey from acquisition of competence to completion. Curr. Opin. Plant Biol. 41, 2331 (2018).

Article CAS PubMed Google Scholar

Shin, J., Bae, S. & Seo, P. J. De novo shoot organogenesis during plant regeneration. J. Exp. Bot. 71, 6372 (2019).

Article Google Scholar

Hayta, S. et al. An efficient and reproducible Agrobacterium-mediated transformation method for hexaploid wheat (Triticum aestivum L.). Plant Methods 15, 121 (2019).

Article CAS PubMed PubMed Central Google Scholar

Ikeuchi, M. et al. Molecular mechanisms of plant regeneration. Annu. Rev. Plant Biol. 70, 377406 (2019).

Article CAS PubMed Google Scholar

Hu, B. et al. Divergent regeneration-competent cells adopt a common mechanism for callus initiation in angiosperms. Regeneration 4, 132139 (2017).

Article CAS PubMed PubMed Central Google Scholar

Atta, R. et al. Pluripotency of Arabidopsis xylem pericycle underlies shoot regeneration from root and hypocotyl explants grown in vitro. Plant J. 57, 626644 (2009).

Article CAS PubMed Google Scholar

Sugimoto, K., Jiao, Y. & Meyerowitz, E. M. Arabidopsis regeneration from multiple tissues occurs via a root development pathway. Dev. Cell 18, 463471 (2010).

Article CAS PubMed Google Scholar

Hu, X. & Xu, L. Transcription factors WOX11/12 directly activate WOX5/7 to promote root primordia initiation and organogenesis. Plant Physiol. 172, 23632373 (2016).

Article CAS PubMed PubMed Central Google Scholar

Liu, J. et al. The WOX11-LBD16 pathway promotes pluripotency acquisition in callus cells during de novo shoot regeneration in tissue culture. Plant Cell Physiol. 59, 734743 (2018).

Article PubMed Google Scholar

Liu, J. et al. WOX11 and 12 are involved in the first-step cell fate transition during de novo root organogenesis in Arabidopsis. Plant Cell 26, 10811093 (2014).

Article CAS PubMed PubMed Central Google Scholar

Gordon, S. P. et al. Pattern formation during de novo assembly of the Arabidopsis shoot meristem. Development 134, 35393548 (2007).

Article CAS PubMed Google Scholar

Meng, W. J. et al. Type-B ARABIDOPSIS RESPONSE REGULATORs specify the shoot stem cell niche by dual regulation of WUSCHEL. Plant Cell 29, 13571372 (2017).

Article CAS PubMed PubMed Central Google Scholar

Kareem, A. et al. PLETHORA genes control regeneration by a two-step mechanism. Curr. Biol. 25, 10171030 (2015).

Article CAS PubMed PubMed Central Google Scholar

Liu, X., Zhu, K. & Xiao, J. Recent advances in understanding of the epigenetic regulation of plant regeneration. aBIOTECH https://doi.org/10.1007/s42994-022-00093-2 (2023).

He, C., Chen, X., Huang, H. & Xu, L. Reprogramming of H3K27me3 is critical for acquisition of pluripotency from cultured Arabidopsis tissues. PLoS Genet. 8, e1002911 (2012).

Article CAS PubMed PubMed Central Google Scholar

Lee, K., Park, O.-S. & Seo, P. J. Arabidopsis ATXR2 deposits H3K36me3 at the promoters of LBD genes to facilitate cellular dedifferentiation. Sci. Signal. 10, eaan0316 (2017).

Article PubMed Google Scholar

Lee, K. et al. Arabidopsis ATXR2 represses de novo shoot organogenesis in the transition from callus to shoot formation. Cell Rep. 37, 109980 (2021).

Article CAS PubMed Google Scholar

Lee, K., Park, O.-S., Choi, C. Y. & Seo, P. J. ARABIDOPSIS TRITHORAX 4 facilitates shoot identity establishment during the plant regeneration process. Plant Cell Physiol. 60, 826834 (2019).

Article CAS PubMed Google Scholar

Liu, H., Zhang, H., Dong, Y. X., Hao, Y. J. & Zhang, X. S. DNA METHYLTRANSFERASE1-mediated shoot regeneration is regulated by cytokinin-induced cell cycle in Arabidopsis. New Phytol. 217, 219232 (2018).

Article CAS PubMed Google Scholar

Hiei, Y., Ishida, Y. & Komari, T. Progress of cereal transformation technology mediated by Agrobacterium tumefaciens. Front. Plant Sci. 5, 628 (2014).

Article PubMed PubMed Central Google Scholar

Ishida, Y., Tsunashima, M., Hiei, Y. & Komari, T. Wheat (Triticum aestivum L.) transformation using immature embryos. Methods Mol. Biol. 1223, 189198 (2015).

Article CAS PubMed Google Scholar

Zhang, W. et al. Regeneration capacity evaluation of some largely popularized wheat varieties in China. Acta Agron. Sin. 44, 208217 (2018).

Article Google Scholar

Wang, K., Liu, H., Du, L. & Ye, X. Generation of marker-free transgenic hexaploid wheat via an Agrobacterium-mediated co-transformation strategy in commercial Chinese wheat varieties. Plant Biotechnol. J. 15, 614623 (2017).

Article CAS PubMed Google Scholar

Lowe, K. et al. Morphogenic regulators Baby boom and Wuschel improve monocot transformation. Plant Cell 28, 19982015 (2016).

Article CAS PubMed PubMed Central Google Scholar

Suo, J. et al. Identification of regulatory factors promoting embryogenic callus formation in barley through transcriptome analysis. BMC Plant Biol. 21, 145 (2021).

Article CAS PubMed PubMed Central Google Scholar

Wang, K. et al. The gene TaWOX5 overcomes genotype dependency in wheat genetic transformation. Nat. Plants 8, 110117 (2022).

Article PubMed Google Scholar

Debernardi, J. M. et al. A GRF-GIF chimeric protein improves the regeneration efficiency of transgenic plants. Nat. Biotechnol. 38, 12741279 (2020).

Article CAS PubMed PubMed Central Google Scholar

Qiu, F. et al. Transient expression of a TaGRF4-TaGIF1 complex stimulates wheat regeneration and improves genome editing. Sci. China Life Sci. 65, 731738 (2022).

Article CAS PubMed Google Scholar

Zhao, L. et al. Dynamic chromatin regulatory programs during embryogenesis of hexaploid wheat. Genome Biol. 24, 7 (2023).

Article CAS PubMed PubMed Central Google Scholar

Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20, 207220 (2019).

Article CAS PubMed Google Scholar

Wang, M. et al. An atlas of wheat epigenetic regulatory elements reveals subgenome divergence in the regulation of development and stress responses. Plant Cell 33, 865881 (2021).

Article PubMed PubMed Central Google Scholar

Sarkar, A. K. et al. Conserved factors regulate signalling in Arabidopsis thaliana shoot and root stem cell organizers. Nature 446, 811814 (2007).

Article CAS PubMed Google Scholar

Yu, J., Liu, W., Liu, J., Qin, P. & Xu, L. Auxin control of root organogenesis from callus in tissue culture. Front. Plant Sci. 8, 1385 (2017).

Article PubMed PubMed Central Google Scholar

Della Rovere, F. et al. Auxin and cytokinin control formation of the quiescent centre in the adventitious root apex of Arabidopsis. Ann. Bot. 112, 13951407 (2013).

Article PubMed PubMed Central Google Scholar

Wu, L. Y. et al. Dynamic chromatin state profiling reveals regulatory roles of auxin and cytokinin in shoot regeneration. Dev. Cell 57, 526542 (2022).

Article CAS PubMed Google Scholar

Ikeuchi, M. et al. A gene regulatory network for cellular reprogramming in plant regeneration. Plant Cell Physiol. 59, 770782 (2018).

Article CAS PubMed Central Google Scholar

Shi, B. et al. Two-step regulation of a meristematic cell population acting in shoot branching in Arabidopsis. PLoS Genet. 12, e1006168 (2016).

Article PubMed PubMed Central Google Scholar

Hao, C. et al. Resequencing of 145 landmark cultivars reveals asymmetric sub-genome selection and strong founder genotype effects on wheat breeding in China. Mol. Plant 13, 17331751 (2020).

Article CAS PubMed Google Scholar

Bisht, A. et al. PAT1-type GRAS-domain proteins control regeneration by activating DOF3.4 to drive cell proliferation in Arabidopsis roots. Plant Cell https://doi.org/10.1093/plcell/koad028 (2023).

Fan, M., Xu, C., Xu, K. & Hu, Y. LATERAL ORGAN BOUNDARIES DOMAIN transcription factors direct callus formation in Arabidopsis regeneration. Cell Res. 22, 11691180 (2012).

Article CAS PubMed PubMed Central Google Scholar

Schulze, S., Schfer, B. N., Parizotto, E. A., Voinnet, O. & Theres, K. LOST MERISTEMS genes regulate cell differentiation of central zone descendants in Arabidopsis shoot meristems. Plant J. 64, 668678 (2010).

Article CAS PubMed Google Scholar

Wang, F. X. et al. Chromatin accessibility dynamics and a hierarchical transcriptional regulatory network structure for plant somatic embryogenesis. Dev. Cell 54, 742757 (2020).

Article CAS PubMed Google Scholar

Xu, M., Du, Q., Tian, C., Wang, Y. & Jiao, Y. Stochastic gene expression drives mesophyll protoplast regeneration. Sci. Adv. 7, eabg8466 (2021).

Article CAS PubMed PubMed Central Google Scholar

Bie, X. M. et al. Trichostatin A and sodium butyrate promotes plant regeneration in common wheat. Plant Signal. Behav. 15, 1820681 (2020).

Article PubMed PubMed Central Google Scholar

Jiang, F. et al. Trichostatin A increases embryo and green plant regeneration in wheat. Plant Cell Rep. 36, 17011706 (2017).

Article CAS PubMed Google Scholar

Zhao, N. et al. Systematic analysis of differential H3K27me3 and H3K4me3 deposition in callus and seedling reveals the epigenetic regulatory mechanisms involved in callus formation in rice. Front. Genet. 11, 766 (2020).

Article CAS PubMed PubMed Central Google Scholar

Daimon, Y., Takabe, K. & Tasaka, M. The CUP-SHAPED COTYLEDON genes promote adventitious shoot formation on calli. Plant Cell Physiol. 44, 113121 (2003).

Article CAS PubMed Google Scholar

Zhai, N. & Xu, L. Pluripotency acquisition in the middle cell layer of callus is required for organ regeneration. Nat. Plants 7, 14531460 (2021).

Article CAS PubMed Google Scholar

Liu, W. et al. Transcriptional landscapes of de novo root regeneration from detached Arabidopsis leaves revealed by time-lapse and single-cell RNA sequencing analyses. Plant Commun. 3, 100306 (2022).

The rest is here:
Uncovering the transcriptional regulatory network involved in ... - Nature.com

Oncopeptides AB – Invitation to presentation of the Q1 report 2023 – Marketscreener.com

Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quarter 2023 at 08:00 (CET) on May 4.

Investors, financial analysts, and media are invited to participate in a webcast and a following QnA session on May 4 at 09:00 (CET). The presentation will be hosted by Monica Shaw, CEO, together with Holger Lembrer, CFO, and will be held in English. It will be published on the website of Oncopeptides in conjunction with the start of the presentation.

Information for participants

If you wish to participate in the webcast, please use the link below. Through the webcast you will have opportunities to ask written questions to the company's leadership.

If you wish to participate via teleconference, please register on the link below. After the registration you will be provided with a phone number and a conference ID to access the conference. You can ask questions to the leadership verbally via the teleconference.

Contact:

Rolf Gulliksen

Email: rolf.gulliksen@oncopeptides.com

Tel: + 46 70 262 96 28

About Oncopeptides

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO.

(C) 2023 Electronic News Publishing, source ENP Newswire

See the rest here:
Oncopeptides AB - Invitation to presentation of the Q1 report 2023 - Marketscreener.com

Join the Autism Summit For Parents Free Virtual Talks to Cover … – GlobeNewswire

London, May 01, 2023 (GLOBE NEWSWIRE) -- London, England -

Autism Parenting Magazine Ltd. will be hosting its Autism Conference in May, continuing to bridge the ever-growing gap between autism experts and special needs families.

Autism Parenting Magazine (APM) is an award-winning publication aimed at improving the quality of life for families affected by autism. For over a decade, APM has been at the forefront of bringing special needs families from around the world together and disseminating invaluable information on the latest interventions and treatments for autism. Today, it has become an essential resource for parents around the world.

APM will soon be hosting its annual Autism Summit For Parents featuring some of the leading experts in the study and management of autism. At least 30 keynote sponsors and speakers will be presenting valuable insights on treatments, interventions, and support strategies.

The event will take place between 12 15 May 2023 and will be hosted online, thus saving families the time and costs related to travel and accommodation. Parents and family members are encouraged to join the event's global audience of some 25,000 attendees and be part of the growing community.

The Autism Conference will offer parents caring for children on the spectrum the opportunity to meet experts in different areas of the autism world. The Summit will benefit the entire autism communityparents, family members, allies, caregivers, and people on the spectrum will find inspiration and gain knowledge from this event.

Interested parties only need to visit APMs website and register for the free pass.

For more information, visit https://autismparentingsummit.com/

The Autism Summit 2023 will have much to offer parents and caregivers as a panel of notable keynote speakers will be explaining cutting-edge concepts based on the latest technologies science has to offer.

Dr. Neil Riordan is one of the early pioneers and experts in applied stem cell research and the founder and chairman of Medistem Panama, Inc., a leading stem cell laboratory and research facility. He is also the founder, chairman, and chief science officer of the Stem Cell Institute in Panama, specializing in the treatment of human diseases and conditions with adult stem cells.

Dr. Gabriel Belfort is the senior vice president of Clinical Development Sciences and Operations at Axial Therapeutics. A physician-scientist focusing on exploring molecular, cellular, and pre-clinical pharmacological aspects of central nervous system function, he serves as the medical director accelerating the clinical development of high-quality novel therapeutics.

Carmellina Stetson is the clinical director of Blue Balloon ABA, North Carolina with a masters degree in Applied Behavior Analysis with a concentration in Autism Studies. Stetson has extensive experience developing programs for individuals with ASD, valuing all individuals learning styles and preferences in order to help each individual reach the highest potential.

Dr. Erik Won is the president & chief medical officer of Wave Neuroscience, a biotechnology company developing innovative solutions to optimize brain function, including autism spectrum disorder. Wave technologies utilize computational neuroanalytics and brain imaging to customize treatment protocols with the aim of restoring optimal neurological function.

Dr. Theoharis Theoharides, a Professor of Pharmacology for 40 years and presently a professor at an institute of neuroImmune medicine, has received multiple awards for his work as well as his humanitarian efforts. He has published myriad scientific papers on neural conditions, including autism spectrum disorder, and has helped formulate unique dietary supplements with over 37 patents and trademarks, including some covering the use of luteolin in autism.

Over the four-day Autism Summit For Parents, these highly acclaimed individuals will be joined by 25 other experts who will speak on a wide range of topics that matter most to special needs families.

About the Publication:

Founded by Mark Blakey, Autism Parenting Magazine is the leading publication for parents of autistic children with an international following. The online magazine has expanded and now offers virtual summits and courses for parents that struggle with special needs children. Daily, the people at Autism Parenting Magazine inspire and entertain its global audience through social media posts. By providing informative content and autism resources, its goal is to improve the quality of life of families affected by autism.

###

For more information about Autism Parenting Magazine, contact the company here:

Autism Parenting MagazineMark Blakey+44(0)203 290 9176press@autismparentingmagazine.comKemp House, 160 City Road, London, EC1V 2NX, United Kingdom

Continued here:
Join the Autism Summit For Parents Free Virtual Talks to Cover ... - GlobeNewswire

Be the Match nonprofit saves woman’s life through stranger’s stem cell transplant – WABC-TV

LOWER MANHATTAN, Manhattan (WABC) -- The ultimate story of kindness resulted in an emotional meeting between a young man from New Jersey and a woman from North Carolina, who is alive today because he supplied her with a stem cell transplant to help her fight leukemia.

At a fundraising benefit in a downtown ballroom, two strangers were about to meet, but it wouldn't be just any meeting. "I don't think I'll even be able to speak when I meet him," Debbie Giroux said.

Giroux was about to meet the man who saved her life.

HOW TO BECOME A BONE MARROW DONOR: Be The Match

"Oh, I think it's going to be pretty emotional," Ryan Keegan said. "We're an emotional family. I didn't want to cry in front of everyone but I think the tears will be flowing."

When his father was diagnosed with leukemia, Keegan became a stem cell donor to help his dad or anyone else suffering from blood cancers.

ALSO READ | SNEAK PEEK: American Museum of Natural History opening state-of-the-art science center

American Museum of Natural History in NYC to open new science center

With a cheek swab, he joined the registry at the nonprofit, Be the Match. And he was.

"It's very surreal because you know that if you don't find that match, you're not going to survive," Giroux said.

Doctors harvested his stem cells at a lab near his home in Howell, New Jersey, and a few months later, they found their way to Charlotte, North Carolina and into Giroux's blood, giving her a second chance at life.

"This year alone we'll save over 7,000 lives, and since our inception, almost 130,000 lives have been saved," said Be the Match CEO Amy Ronneberg.

Be the Match doesn't just run the registry, it also helps families cover their steep costs during the year it can take to recover after a bone marrow transplant.

"I think we're living proof that this works and join the registry and make the difference, you can save someone's life," Keegan said.

----------* Get Eyewitness News Delivered * More Manhattan news* Send us a news tip* Download the abc7NY app for breaking news alerts * Follow us on YouTube

View original post here:
Be the Match nonprofit saves woman's life through stranger's stem cell transplant - WABC-TV

Doctor’s Tip: How to prevent and survive breast cancer – Glenwood Springs Post Independent

Breast cancer is the number one type of cancer in the U.S, aside from skin cancer. Every year, around 280,000 women are diagnosed with it and some 43,000 die from it.

Some of the billions of cells in our bodies are always mutating. Mammograms and self-breast exams are said to provide early detection of breast cancer, but Dr. Michael Greger points out that this is actually late detection, because by the time breast cancer is diagnosed by these methods it has been present for years, starting with the first abnormal cell. Humans evolved to eat plants, and plants contain micronutrients that destroy mutant cells before they propagate and cause cancer; animal products lack this ability.

If you are a woman and want to do everything you can to prevent breast cancer, read the chapter on breast cancer in Dr. Gregers book How Not to Die, and search breast cancer on his website nutritionfacts.org. If youre a breast cancer survivor, read The Cancer Survivors Guide, Foods That Help You Fight Back! by Neal Barnard, M.D.

Following are some important tips to prevent breast cancer, found in these two books plus an article in the January/February issue of Nutrition Action titled, Cancer, How to Lower Your Risk.

Alcohol, even in small amounts, was declared in 2014 by the World Health Organization to be a definitive human breast carcinogen, due to DNA damage, oxidative stress, and increase in estrogen levels.

Melatonin, the sleep hormone, appears to have a protective effect against breast cancer. Melatonin levels are lowered by bright lights during pre-bedtime hours from sources such as light bulbs, TV screens, computers and smart phones. For unknown reasons, eating meat lowers melatonin levels and vegetables raise them.

Estrogen in excess increases breast cancer risk, and women need to be hesitant about taking post-menopausal hormones bio-identical hormones have not been shown to be any safer. Fat cells produce estrogen, so to avoid breast cancer its important to maintain ideal body weight.

Saturated fat present in animal products, cooking oils and coconut products (other than coconut water) increases breast cancer risk.

Exercise, such as brisk walking for at least 30-60 minutes every day, lowers breast cancer risk due to loss of excess fat and lower levels of inflammation.

Heterocyclic Amines (HCAs) are carcinogens produced by cooking meat (including chicken) and seafood at high temperatures, such as roasting, pan frying, grilling, and baking. According to Dr. Greger, One of the most abundant HCAs in cooked meat was found to have potent estrogen-like effects, fueling human breast-cancer cell growth.

Lignans are plant estrogens (a.k.a. phytoestrogens) activated by good gut bacteria, that dampen the effects of the bodys own estrogen, according to Dr. Greger. Lignans are particularly plentiful in flaxseeds, and are also found in berries, whole grains and dark, leafy greens.

Cholesteral, when levels are high, may increase breast cancer risk, according to Dr. Greger thought to be due to our bodies using cholesterol to make estrogen or to shore up tumor cell membranes to help the cancer migrate and invade more tissue. Unfortunately, reducing levels with statin drugs has not been shown to reduce breast cancer risk.

Fiber present in plant but not animal products helps remove estrogen via the GI tract, thereby lowering breast cancer risk. Several studies show that for every 29 grams of fiber intake per day there is a 15% lower risk of breast cancer.

Carotinoids are micronutrients found in green, orange and red fruit and vegetables and have been found to protect against breast cancer. Apple peels in particular contain a compound that activates breast tumor-suppressor genes.

Sulforaphane, a compound in cruciferous vegetables (like broccoli, cabbage, kale, cauliflower) suppresses the ability of breast cancer stem cells to form tumors the cause of recurrence of breast cancer that occasionally happens after years of remission. Cooking destroys the enzyme that releases sulforaphane, so some needs to be eaten raw or eat some raw cruciferous vegetables before eating cooked.

Soy? Many people have the misconception that soy contains estrogen and should therefore be avoided to prevent breast cancer. The fact is that if the weak, estrogen-like compounds in soy attach to breast tissue receptors, stronger, harmful estrogens are prevented from attaching, resulting in a lower risk of breast cancer. Asian women eat a diet high in soy products, and have much lower risk of breast cancer compared to women on a typical Western diet.

Dr. Feinsinger is a retired family physician with special interest in disease prevention and reversal through nutrition. Free services through Center For Prevention and The Peoples Clinic include: one-hour consultations, shop-with-a-doc at Carbondale City Market, and cooking classes. Call 970-379-5718 for appointment, or emailgfeinsinger@comcast.net.

Continued here:
Doctor's Tip: How to prevent and survive breast cancer - Glenwood Springs Post Independent

All You Need to Know about a Bone Marrow Transplant – Metropolis Healthcare

What is a Bone Marrow Transplant?

A bone marrow transplant is a medical procedure for patients with certain cancers and other diseases such as severe aplastic anaemia, immune deficiency disorders, etc. Bone marrow is a spongy material present inside the bones which produces and stores blood cells. The transplantation of blood stem cells replaces damaged bone marrow with functioning, healthy bone marrow; rejuvenates the immune system to fight back the diseased or damaged cells; and assists in the smooth recovery of the patient.

At a young stage, your blood cells are called hematopoietic stem cells. After maturing they travel into your blood from your bone marrow, therefore a bone marrow transplant is also called a stem cell transplant.

A bone marrow transplant involves taking stem cells from your bone marrow, then filtering those cells and then giving these filtered stem cells back to the donor or to another person.

The main aim of a bone marrow transplant is to infuse healthy bone marrow cells into a person. Since,1998 this procedure has been used to successfully treat diseases such as aplastic anaemia, immune deficiency disorder, lymphomas, leukemias and some solid tumor cancers.

Bone marrow transplant is done to cure many types of cancer and some other diseases. Often to cure cancer, the doses of chemotherapy that a patient is subjected to are quite high and this high-frequency radiation can permanently damage or destroy the stem cells in the bone marrow therefore, a transplant may be needed.

In some cases, the stem cells in the bone marrow are already damaged by the occurrence of a disease and so a transplant is needed.

A bone marrow transplant may help you by:

The risks and benefits must be weighed in a thorough discussion with your healthcare emphasising why a Bone Marrow Transplant.

Following are the examples of the most common diseases that may benefit from a bone marrow transplant:

Doctors are also able to perform anumbilical cord blood transplant where stem cells are collected from the umbilical cord immediately after the delivery of an infant. These stem cells can reproduce into mature, functioning blood cells quicker and more effectively than the stem cells taken from the bone marrow of another child or adult. These stem cells are tested, typed, counted, and frozen until they are needed for a transplant.

Only your doctor can decide whether or not a bone marrow transplant is the best course of action for you. With a physical examination and multiple tests, your doctor will be able to talk to you about what type of procedure is your best bet and what you can expect.

If your doctor and you reach a common ground and decide to go ahead with a bone marrow transplant, finding a donor will start after matching your bone marrow transplant will be finalised.

A few days before the transplant your doctor will put a tube called a central venous catheter into a vein in your chest. Your doctor along with your medical team will use it to take blood and give you medicine and It will stay there until after your treatment.

A bone marrow transplant is a widely accepted, associated medical procedure for certain types of cancer and other diseases that could damage or destroy the bone marrow of a patient. The transplanting of blood stem cells has pronged applications to produce new blood cells, promote new marrow growth, and regenerate the immune system. This as well promotes patient recovery and survival rates.

However, continuous follow-up care is essential for the patients. Also, a pre-procedure discussion with a healthcare provider and specialists in bone marrow transplants is advisable to learn the risks and benefits. Metropolis Healthcare is a leading pathology lab and diagnostic centre with a multinational network, a comprehensive range of 4000+ clinical laboratory tests and profiles, and senior pathologists to deliver diagnostic solutions. They offer the convenience of a stay-at-home blood collection service, online tracking of samples, and report download from a single app.

They are widely recognized by several brands and institutions and offer a comprehensive Corporate Social Responsibility program. Bone marrow transplant is a boon to many patients and new methods and diagnoses to improve treatment options and decrease complications and side effects are continually being discovered.

LikeLoveHahaWowSadAngry

Go here to read the rest:
All You Need to Know about a Bone Marrow Transplant - Metropolis Healthcare

Chicago Med Season 8 Episode 19 Review: Look Closely And You … – TV Fanatic

Hospital politics are always messy. Even when no corporate overlord is trying to steer the institution in a direction that might not be best for patients, board members often clash with healthcare providers.

Chicago Med Season 8 Episode 19 is the latest medical drama to explore what happens when a non-doctor with their own agenda gains a controlling interest in the hospital (both The Good Doctor and New Amsterdam offered similar stories in 2022).

Jack seemed all right as a hospital owner -- until he wasn't. But his latest victory was utterly predictable.

With all the noise Sharon, George, and Will kept making about how Vernon would swing the vote their way, how could he not betray them at the last second?

Will went to a ton of trouble to ensure Vernon could vote while Jack tried his hardest to interfere -- only for Vernon to gain a new perspective after his surgery.

Surprise! NOT. Vernon hadn't considered the issue before falling ill; he only went along with Sharon because he'd been on the board for 23 years and trusted her opinion.

Although Vernon came through the surgery fine, thanks to OR 2.0 and Abrams' surgical skills, I'd think he'd need more than an hour in the recovery room before he could sit through a board meeting, even by video. The man just had brain surgery!

Television brain tumor survivors often wake up with drastically different personalities, so it was likely that Vernon would support Jack for that reason. The only twist was that 2.0's saving his life made him decide that Jack's vision for the hospital was the way to go.

I don't know George and Sharon's counterarguments, but they allowed Jack to frame the discussion in a way that benefited his position. Why is going to for-profit status the only way to ensure Gaffney continues offering cutting-edge medical technology?

Instead of arguing that for-profit status is contrary to the hospital's established mission, which board members didn't appear to care about, the counterargument should have focused on for-profit status being unnecessary to achieve the goal of being a leader in the medical tech sector.

They could have focused on the idea that Gaffney could be that leader AND continue to provide care to all patients, regardless of income level.

This missed opportunity will change Gaffney forever -- or at least until the board votes to repeal the for-profit status. But the irony of Will's plan causing the opposite result of what he wanted was SO delicious!

Grace balked at Will asking for her expertise when it meant that Jack's proposal might be defeated, but will she change her tune now that Vernon votes for the plan?

What Will did wasn't entirely unethical.

Yes, getting Vernon's wife to agree to surgery meant Vernon could participate in the board meeting. But Vernon needed the surgery anyway; he had to be intubated, with no guarantee that the alternative treatment would do anything to resolve his tumor.

Grace might have felt used, but she DID help Vernon get the needed treatment, so there was that.

Archer's behavior was a lot more questionable. At least half the reason he broke Kira's confidentiality was to get back at Asher for telling Sean about Archer's medical condition.

He gave her a BS explanation about Kimberly being Kira's proxy if something went wrong during surgery, but come on. Every other word out of his mouth was about how now Asher believed in confidentiality when she didn't before.

This petty behavior and refusal to recognize patients' rights made me hate Archer when he arrived at Med. He's been more tolerable lately and, in some ways, more relatable.

But not this time. He was wrong to violate Kira's confidentiality, and even if Asher was wrong to break his, that's no excuse. Didn't Archer learn that two wrongs don't make a right long before he was old enough for medical school?

The Kira situation was surprisingly opposite of what I expected.

When Chicago Med Season 8 Episode 19 spoilers stated that Asher and Archer would be dealing with a stem cell disease and a pregnant daughter, I predicted that the mother would want her daughter to give up the baby so that she could use its stem cells.

That would have been a fascinating ethical dilemma, but the actual story was fantastic. Still, I wondered why the doctors couldn't use the stem cells from the non-viable fetus to cure Kimberly's disease, assuming they were a match.

I'm glad that Marcel helped Tanaka-Reid get his self-confidence back.

I could have done without most of this story, which featured a bunch of residents acting like high school students. The teasing and bullying were inappropriate behavior. Tanaka-Reid acted like the stereotypical nerdy kid who pretends not to care but secretly fears his bullies are right to tease him.

Marcel was right that the other residents were reacting to Tanaka-Reid acting like he was far superior for the last year or so, but again -- two wrongs don't make a right. And in this case, there was far too much immature behavior for my liking.

At least Marcel and Tanaka-Reid have settled into a more respectful mentor/mentee relationship! Tanaka-Reid was insufferable when he used to try to replace Marcel's judgment with his own.

Charles' main story was interesting. I liked that Maggie could interpret ASL so that they could catch Sandy making up stories about what her brother was communicating.

Aiden's desire to keep the imaginary voices in his head because he could HEAR them was also interesting, and I wish there'd been more time to develop that part of the story.

And what was with Lilian's obnoxious brother? Charles went from one language barrier to another in that last scene, and Pavo did nothing to endear himself to viewers. I wondered if he thinks Charles is too good for Liliana or believes a doctor must have an ulterior motive for dating his sister.

Your turn, Chicago Med fanatics! Hit the big, blue SHOW COMMENTS button and let us know your thoughts.

Don't forget you can watch Chicago Med online on TV Fanatic.

Chicago Med airs on NBC on Wednesdays at 8/7c.

Edit Delete

Jack Ori is a senior staff writer for TV Fanatic. His debut young adult novel, Reinventing Hannah, is available on Amazon. Follow him on Twitter.

Read more:
Chicago Med Season 8 Episode 19 Review: Look Closely And You ... - TV Fanatic